Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery (HERACLES)
Primary Purpose
Cardiovascular Diseases, Valvular Heart Disease
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Hypertonic saline
0.9% saline
Sponsored by
About this trial
This is an interventional prevention trial for Cardiovascular Diseases
Eligibility Criteria
Inclusion Criteria:
- Adult patients undergoing cardiac surgery for ischemic or valvular heart disease
Exclusion Criteria:
- Patients unable to give informed consent
- Patients with age <18 years
- Pregnancy or breastfeeding
- Left-ventricular ejection fraction (LVEF) < 30% preoperatively
- Preexisting renal insufficiency with an eGFR <30 ml/min/1.73m2
- Patients with postoperative circulatory support devices such as LVAD, IABP, Impella, ECMO
- Preexisting serum sodium of >145mmol/l or <135 mmol/L
- Preexisting serum chloremia >107mmol/l or < 98 mmol/L
- Systemic steroid therapy (at any dose at time of inclusion)
- Chronic liver disease (bilirubin >3 mg.dl)
- Any signs of infection or sepsis defined as clear clinical evidence for active infection or current antibiotic therapy
Sites / Locations
- Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
7.3% NaCl (intervention)
0.9% NaCl (comparator)
Arm Description
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Outcomes
Primary Outcome Measures
total cumulative amount of fluids infused
Secondary Outcome Measures
postoperative weight gain
total postoperative cumulative urinary output
total cumulative dose of inopressors per kg bodyweight /hour
cumulation of norepinephrine and epinephrine
time on inopressors
norepinephrine and/or epinephrine
variation in renal function markers
renal damage maker (TIMP2-IGFB, creatinine)
variation in acid-base homeostasis
pH, base excess, lactate, bicarbonate, electrolytes
variation in immune function
mHLA-DR
time on the ventilator
occurence of infection
length of stay
time to ICU/hospital-discharge
readmissions to the ICU
mortality
Full Information
NCT ID
NCT03280745
First Posted
August 23, 2017
Last Updated
March 23, 2020
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT03280745
Brief Title
Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery
Acronym
HERACLES
Official Title
Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
February 27, 2018 (Actual)
Primary Completion Date
May 27, 2019 (Actual)
Study Completion Date
September 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Background: Volume replacement strategies and type of fluid used in patients undergoing cardiac surgery have changed during the last years. Currently used crystalloid solutes have a variable composition and a major impact on organ function and outcome. Additionally critically ill patients are prone to fluid overload, which is despite common perception, not a benign occurrence as it is associated with prolonged ICU- and hospital length of stay and increased mortality rates. Fluid resuscitation using bolus or continuous infusion of hypertonic saline was used for more than thirty years. Only a few studies have been conducted so far, but they showed that infusion of hypertonic saline results in less volume administered, increased renal function less weight gain in critically ill patients when compared to other crystalloids.
Aim: This preliminary randomized controlled double-blind study aims to identify whether fluid resuscitation using hypertonic saline (HS) when used in addition to lactated Ringers solution results in less total fluid amount administered in patients following cardiac surgery. Additionally we want to evaluate whether the use of hypertonic saline results less need for pharmacological cardiocirculatory support, increased renal function, less postoperative volume overload shortened post-cardiac bypass immune suppression and increased postoperative outcomes.
Study intervention: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl or 0.9% NaCl by infusion pump over 60 minutes. If necessary, fluid resuscitation will thereafter be performed with Ringer's lactate to normalize peripheral perfusion and to allow weaning of vasopressors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Valvular Heart Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl or 0.9% NaCl by infusion pump over 60 minutes. If necessary, fluid resuscitation will be performed with Ringer's lactate to normalize peripheral perfusion and to allow weaning of vasopressors.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
double-blind
Allocation
Randomized
Enrollment
165 (Actual)
8. Arms, Groups, and Interventions
Arm Title
7.3% NaCl (intervention)
Arm Type
Active Comparator
Arm Description
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
Arm Title
0.9% NaCl (comparator)
Arm Type
Active Comparator
Arm Description
At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Intervention Type
Drug
Intervention Name(s)
Hypertonic saline
Other Intervention Name(s)
7.9% NaCl
Intervention Description
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
Intervention Type
Drug
Intervention Name(s)
0.9% saline
Other Intervention Name(s)
normal saline
Intervention Description
At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Primary Outcome Measure Information:
Title
total cumulative amount of fluids infused
Time Frame
daily until ICU discharge, max until postoperative day 90
Secondary Outcome Measure Information:
Title
postoperative weight gain
Time Frame
until postoperative day 6
Title
total postoperative cumulative urinary output
Time Frame
daily until ICU discharge, max until postoperative day 90
Title
total cumulative dose of inopressors per kg bodyweight /hour
Description
cumulation of norepinephrine and epinephrine
Time Frame
until ICU discharge, max until postoperative day 90
Title
time on inopressors
Description
norepinephrine and/or epinephrine
Time Frame
from ICU admission until stop of inopressors, max until postoperative day 90
Title
variation in renal function markers
Description
renal damage maker (TIMP2-IGFB, creatinine)
Time Frame
until postoperative day 6
Title
variation in acid-base homeostasis
Description
pH, base excess, lactate, bicarbonate, electrolytes
Time Frame
until postoperative day 6
Title
variation in immune function
Description
mHLA-DR
Time Frame
until postoperative day 6
Title
time on the ventilator
Time Frame
from ICU admission until time of extubation, maximum 90 days
Title
occurence of infection
Time Frame
occurence of infection during the index hospitalisation or subsequent admissions due to infection upto 90 postoperative days
Title
length of stay
Description
time to ICU/hospital-discharge
Time Frame
time to ICU/hospital-discharge however long this may take, maximum 90 days
Title
readmissions to the ICU
Time Frame
readmissions to the ICU within postoperative 90 days
Title
mortality
Time Frame
until postoperative day 90
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients undergoing cardiac surgery for ischemic or valvular heart disease
Exclusion Criteria:
Patients unable to give informed consent
Patients with age <18 years
Pregnancy or breastfeeding
Left-ventricular ejection fraction (LVEF) < 30% preoperatively
Preexisting renal insufficiency with an eGFR <30 ml/min/1.73m2
Patients with postoperative circulatory support devices such as LVAD, IABP, Impella, ECMO
Preexisting serum sodium of >145mmol/l or <135 mmol/L
Preexisting serum chloremia >107mmol/l or < 98 mmol/L
Systemic steroid therapy (at any dose at time of inclusion)
Chronic liver disease (bilirubin >3 mg.dl)
Any signs of infection or sepsis defined as clear clinical evidence for active infection or current antibiotic therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joerg C Schefold, MD
Organizational Affiliation
Department of Intensive Care, Inselspital, Bern University Hospital, Bern, Switzerland
Official's Role
Study Director
Facility Information:
Facility Name
Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
31200756
Citation
Pfortmueller CA, Messmer AS, Hess B, Reineke D, Jakob L, Wenger S, Waskowski J, Zuercher P, Stoehr F, Erdoes G, Luedi MM, Jakob SM, Englberger L, Schefold JC. Hypertonic saline for fluid resuscitation after cardiac surgery (HERACLES): study protocol for a preliminary randomised controlled clinical trial. Trials. 2019 Jun 14;20(1):357. doi: 10.1186/s13063-019-3420-6.
Results Reference
derived
Learn more about this trial
Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery
We'll reach out to this number within 24 hrs